We show here that hSTAT5BN642H acts as a driver mutation in the development of leukemia and lymphoma and propose that upstream inhibition of JAK activation or the chromatin-remodeling partners of STAT5 could be an alternative targeting strategy for enhanced STAT5 activation. Here, STAT5A is linked to leukemia.